2025
JUNE
NEW RENAISSANCE
INTERNATIONAL SCIENTIFIC AND PRACTICAL CONFERENCE
VOLUME 2
|
ISSUE 6
295
ADVANCEMENTS IN HEART FAILURE MANAGEMENT: FROM
NEUROHORMONAL MODULATION TO EMERGING REGENERATIVE
THERAPIES
¹Shermatov Bektosh Bayon o‘g‘li
²Shodiyev Xumayun Ilhom o‘g‘li
³Shukurlayev Adhamjon Odil o‘g‘li
¹'²'³Samarkand State Medical University DKTF, Department of Internal Medicine, Cardiology
and Functional Diagnostics! Second-year clinical residents
https://doi.org/10.5281/zenodo.15637131
Research objective
Heart failure (HF) is a complex clinical syndrome characterized by the heart’s inability to
pump sufficient blood to meet the metabolic demands of the div. It is a final common pathway
for many cardiovascular diseases and remains one of the leading causes of hospitalization,
morbidity, and mortality worldwide. The primary goal of this research is to analyze the evolution
of heart failure management, focusing on the progression from traditional neurohormonal
modulation to advanced regenerative therapies and personalized medicine strategies. The
multifactorial pathophysiology of HF involves not only systolic or diastolic dysfunction but also
neurohormonal dysregulation, inflammatory processes, oxidative stress, mitochondrial
dysfunction, and extracellular matrix remodeling. Traditionally, HF has been classified based on
left ventricular ejection fraction (LVEF) into HF with reduced EF (HFrEF), preserved EF
(HFpEF), and mid-range EF (HFmrEF). However, evolving evidence suggests a need for more
phenotype-specific treatment approaches that incorporate biomarkers, imaging data, and genetic
profiling.
Introduction
The cornerstone of HFrEF treatment has historically involved neurohormonal
antagonism. Angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers
(ARBs), beta-blockers, and mineralocorticoid receptor antagonists (MRAs) have demonstrated
significant reductions in mortality and hospitalization in large randomized controlled trials. More
recently, angiotensin receptor-neprilysin inhibitors (ARNIs), particularly sacubitril/valsartan,
have revolutionized the therapeutic landscape by providing superior outcomes compared to
traditional RAAS inhibition, as demonstrated in the PARADIGM-HF trial. Sodium-glucose co-
transporter 2 (SGLT2) inhibitors, initially developed for diabetes management, have now
emerged as a class of drugs with robust cardiovascular and renal benefits in both diabetic and
non-diabetic HF patients. DAPA-HF and EMPEROR-Reduced trials have confirmed their
efficacy in reducing HF-related hospitalizations and cardiovascular death. These pharmacologic
advancements are often complemented by device-based therapies. Cardiac resynchronization
therapy (CRT) and implantable cardioverter-defibrillators (ICDs) are standard in patients with
specific conduction abnormalities and at high risk of sudden cardiac death. Hemodynamic
monitoring devices, such as CardioMEMS, enable early detection of volume overload and
preemptive management of decompensation.
Materials and Methods
In HFpEF, where therapeutic options have traditionally been limited, recent trials like
EMPEROR-Preserved and DELIVER have shown that SGLT2 inhibitors also confer meaningful
benefits, shifting the treatment paradigm in this previously untreatable phenotype. Ongoing
investigations into the use of mineralocorticoid receptor antagonists, ARNIs, and anti-fibrotic
2025
JUNE
NEW RENAISSANCE
INTERNATIONAL SCIENTIFIC AND PRACTICAL CONFERENCE
VOLUME 2
|
ISSUE 6
296
agents in HFpEF patients offer hope for improved outcomes. Biomarkers such as natriuretic
peptides (BNP, NT-proBNP), troponins, galectin-3, ST2, and growth differentiation factor-15
(GDF-15) are increasingly used for diagnosis, risk stratification, and therapeutic monitoring.
Novel biomarkers including circulating microRNAs, exosomes, and proteomic signatures are
under active exploration for their potential to refine phenotyping and guide individualized
therapy. Advanced imaging techniques such as speckle-tracking echocardiography, cardiac MRI
with late gadolinium enhancement, and nuclear imaging for myocardial metabolism provide
valuable insights into myocardial structure and function, guiding therapeutic decisions.
Results
Regenerative therapies represent a frontier in HF treatment, aiming to restore myocardial
integrity and function. Stem cell-based approaches, including mesenchymal stem cells (MSCs),
cardiac progenitor cells, and induced pluripotent stem cells (iPSCs), have demonstrated variable
results in clinical trials, often limited by delivery efficiency, cell survival, and host immune
response. Bioengineered tissues, gene editing techniques like CRISPR/Cas9, and extracellular
vesicle therapies are being actively studied for their potential to reverse or mitigate myocardial
injury. Gene therapy targeting SERCA2a, adenylyl cyclase, and nitric oxide pathways has shown
promise in preclinical models and early-phase trials. Moreover, tissue engineering with
decellularized scaffolds and 3D bioprinting of cardiac patches represents an innovative approach
toward myocardial regeneration.
The integration of artificial intelligence (AI) and machine learning into HF care has
enabled the development of predictive models for readmission risk, therapy optimization, and
phenotypic classification. Digital health tools, including wearable devices, remote patient
monitoring, and telemedicine, have become essential components of chronic HF management,
particularly in the post-COVID era. Multidisciplinary HF clinics involving cardiologists,
pharmacists, nurses, nutritionists, and palliative care specialists have demonstrated significant
benefits in patient adherence, quality of life, and survival.
Conclusion
Despite these advances, challenges remain in addressing disparities in access to care,
medication adherence, and disease awareness, particularly in low- and middle-income countries.
Socioeconomic factors, health literacy, and comorbidities like chronic kidney disease, diabetes,
anemia, and frailty complicate management strategies. Moreover, sex-specific differences in HF
presentation and response to therapy are increasingly recognized, necessitating inclusive research
and sex-aware clinical decision-making.
In conclusion, heart failure management has transitioned from symptomatic relief to a
comprehensive, mechanistically targeted, and increasingly personalized approach. The future of
HF care lies in integrating molecular insights, advanced therapeutics, and patient-centered care
models to improve outcomes and quality of life for this growing patient population. Continued
research, innovation, and equitable implementation of evidence-based practices are crucial for
transforming the HF treatment landscape in the coming decades.
REFERENCE
S
1.
Andryev S. et al. Experience with the use of memantine in the treatment of
cognitive disorders //Science and innovation. – 2023. – Т. 2. – №. D11. – С. 282-288.
2025
JUNE
NEW RENAISSANCE
INTERNATIONAL SCIENTIFIC AND PRACTICAL CONFERENCE
VOLUME 2
|
ISSUE 6
297
2.
Antsiborov S. et al. Association of dopaminergic receptors of peripheral
blood lymphocytes with a risk of developing antipsychotic extrapyramidal diseases
//Science and innovation. – 2023. – Т. 2. – №. D11. – С. 29-35.
3.
Asanova R. et al. Features of the treatment of patients with mental
disorders and cardiovascular pathology //Science and innovation. – 2023. – Т. 2. – №.
D12. – С. 545-550.
4.
Begbudiyev M. et al. Integration of psychiatric care into primary care
//Science and innovation. – 2023. – Т. 2. – №. D12. – С. 551-557.
5.
Bo’Riyev B. et al. Features of clinical and psychopathological examination
of young children //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 558-563.
6.
Borisova Y. et al. Concomitant mental disorders and social functioning of
adults with high-functioning autism/asperger syndrome //Science and innovation. – 2023.
– Т. 2. – №. D11. – С. 36-41.
7.
Ivanovich U. A. et al. Efficacy and tolerance of pharmacotherapy with
antidepressants in non-psychotic depressions in combination with chronic brain ischemia
//Science and Innovation. – 2023. – Т. 2. – №. 12. – С. 409-414.
8.
Nikolaevich R. A. et al. Comparative effectiveness of treatment of
somatoform diseases in psychotherapeutic practice //Science and Innovation. – 2023. – Т.
2. – №. 12. – С. 898-903.
9.
Novikov A. et al. Alcohol dependence and manifestation of autoagressive
behavior in patients of different types //Science and innovation. – 2023. – Т. 2. – №. D11.
– С. 413-419.
10.
Pachulia Y. et al. Assessment of the effect of psychopathic disorders on
the dynamics of withdrawal syndrome in synthetic cannabinoid addiction //Science and
innovation. – 2023. – Т. 2. – №. D12. – С. 240-244.
11.
Pachulia Y. et al. Neurobiological indicators of clinical status and
prognosis of therapeutic response in patients with paroxysmal schizophrenia //Science
and innovation. – 2023. – Т. 2. – №. D12. – С. 385-391.
12.
Pogosov A. et al. Multidisciplinary approach to the rehabilitation of
patients with somatized personality development //Science and innovation. – 2023. – Т.
2. – №. D12. – С. 245-251.
13.
Pogosov A. et al. Rational choice of pharmacotherapy for senile dementia
//Science and innovation. – 2023. – Т. 2. – №. D12. – С. 230-235.
14.
Pogosov S. et al. Gnostic disorders and their compensation in
neuropsychological syndrome of vascular cognitive disorders in old age //Science and
innovation. – 2023. – Т. 2. – №. D12. – С. 258-264.
15.
Pogosov S. et al. Prevention of adolescent drug abuse and prevention of
yatrogenia during prophylaxis //Science and innovation. – 2023. – Т. 2. – №. D12. – С.
392-397.
16.
Pogosov S. et al. Psychogenetic properties of drug patients as risk factors
for the formation of addiction //Science and innovation. – 2023. – Т. 2. – №. D12. – С.
186-191.
2025
JUNE
NEW RENAISSANCE
INTERNATIONAL SCIENTIFIC AND PRACTICAL CONFERENCE
VOLUME 2
|
ISSUE 6
298
17.
Prostyakova N. et al. Changes in the postpsychotic period after acute
polymorphic disorder //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 356-360.
18.
Zuhridinovna, J. D., & Farrukh, S. (2024). Modern Imaging Techniques
for Early Detection of Retinal Degeneration. American Journal of Bioscience and
Clinical Integrity, 1(11), 22–34.
19.
Prostyakova N. et al. Issues of professional ethics in the treatment and
management of patients with late dementia //Science and innovation. – 2023. – Т. 2. – №.
D12. – С. 158-165.
20.
Prostyakova N. et al. Sadness and loss reactions as a risk of forming a
relationship together //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 252-257.
21.
Prostyakova N. et al. Strategy for early diagnosis with cardiovascular
diseaseisomatized mental disorders //Science and innovation. – 2023. – Т. 2. – №. D12. –
С. 166-172.
22.
Rotanov A. et al. Comparative effectiveness of treatment of somatoform
diseases in psychotherapeutic practice //Science and innovation. – 2023. – Т. 2. – №.
D12. – С. 267-272.
23.
Rotanov A. et al. Diagnosis of depressive and suicidal spectrum disorders
in students of a secondary special education institution //Science and innovation. – 2023.
– Т. 2. – №. D11. – С. 309-315.
24.
Rotanov A. et al. Elderly epilepsy: neurophysiological aspects of non-
psychotic mental disorders //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 192-
197.
25.
Rotanov A. et al. Social, socio-cultural and behavioral risk factors for the
spread of hiv infection //Science and innovation. – 2023. – Т. 2. – №. D11. – С. 49-55.
26.
Rotanov A. et al. Suicide and epidemiology and risk factors in oncological
diseases //Science and innovation. – 2023. – Т. 2. – №. D12. – С. 398-403.
27.
Sedenkov V. et al. Clinical and socio-demographic characteristics of
elderly patients with suicide attempts //Science and innovation. – 2023. – Т. 2. – №. D12.
– С. 273-277.
28.
Sedenkov V. et al. Modern methods of diagnosing depressive disorders in
neurotic and affective disorders //Science and innovation. – 2023. – Т. 2. – №. D12. – С.
361-366.
